Sanofi Group - SNY Net earnings per share (EPS TTM)

Official company branding of Sanofi S.A. (SNY)

Sanofi (SNY) management is effectively reallocating resources toward innovative immunology, enhancing R&D transparency. Changes in the rolling net income per share help identify yield anomalies, where the 1.92 mark indicates the current state. Strict patents ensure monopoly pricing power for vaccines, while targeted deals with biotech startups systematically refresh the company's development pipeline.

SNY (Sanofi) Net earnings per share for the last four quarters history from 07/04/2022 to 11/15/2026

Analytical breakdowns for Sanofi

- current quotes and average value forecast:
Price Chart Sanofi S.A.|SNY - Price Target Chart
- issuer market value details:
Market Capitalization Sanofi|SNY - Business Value
- business book valuation details:
Book Value per Share Sanofi|SNY - Book Valuation of Business|Market Value to Book Value Ratio sanofi.com|SNY - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital Sanofi|SNY - Long-Term Indebtedness to Equity|Short-Term Debt to Equity sanofi.com|SNY - Company Total Debt Obligations|Debts to Book Capitalization Sanofi SA|SNY - Company Long-Term Debts|Company Short-Term Debt Sanofi|Quick Liquidity sanofi.com
- net income and valuation multiples indicators:
SNY - Company Net Income|Projected Future Earnings Sanofi|SNY - Market Cap to Net Income|Forward P/E Multiple Sanofi Group|SNY - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sanofi|SNY - Operating income before deduction of amortization|Earnings per share for the last twelve months Sanofi|SNY - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months sanofi.com|SNY - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Sanofi
- total revenue and sales volume data:
SNY - Company Annual Revenue|Projected Sales Volume Sanofi S.A.|SNY - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Sanofi SA|SNY - Sales Growth YoY (TTM)
Fundamental company analysis:sanofi.com (SNY)
Manufactured products of Sanofi Aventis

Professional capital evaluates Sanofi (SNY) through the lens of capital expenditure efficiency across its network of global laboratories and plants. By analyzing the change in TTM net income per share, the investor identifies the final profit allocated per security, which allows for an objective measurement of business profitability and confirms the asset's fundamental stability regardless of reporting lags.

Competitors of Sanofi (SNY)

LLY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months AbbVie Inc|AZN: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NVS|MRK (merck.com) - Net earnings per share (EPS TTM)|novonordisk.com (NVO) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) AMGN|Pfizer - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) BMY (Bristol Myers Squibb Company)|Net earnings per share for the trailing year GSK Corp|TAK: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Teva Pharmaceuticals (TEVA)|Dr. Reddy's (RDY) - Earnings per share for the last twelve months|VTRS (Viatris) - Earnings per share for the last twelve months|Earnings per share for the last twelve months roivant.com|Net earnings per share (EPS TTM) Zai Lab Ltd.|Earnings per share for the last twelve months bauschhealth.com (BHC)|Net earnings per share for the last four quarters cosmosholdingsinc.com